Constellation Pharmaceuticals, Inc. (CNST) financial statements (2022 and earlier)

Company profile

Business Address 215 FIRST STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments382,080421,448489,354520,513358,849383,93489,066
Cash and cash equivalents113,983163,693116,996179,112190,464334,33278,977
Short-term investments268,097257,755372,358341,401168,38549,60210,089
Other undisclosed current assets7,8687,1615,1122,5862,8173,0553,144
Total current assets:389,948428,609494,466523,099361,666386,98992,210
Noncurrent Assets
Operating lease, right-of-use asset2,8113,5418,7109,37810,10310,74511,372
Property, plant and equipment1,6671,4971,3951,4438679711,149
Restricted cash and investments3,2333,233425425425425425
Deferred costs      61
Other undisclosed noncurrent assets5,0004,974453453   
Total noncurrent assets:12,71113,24510,98311,69911,39512,14113,007
TOTAL ASSETS:402,659441,854505,449534,798373,061399,130105,217
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,32915,8659,9208,9525,48911,9898,030
Accounts payable4,5199,8535,3715,6593,5587,2784,983
Accrued liabilities532467396425295184265
Employee-related liabilities2,2785,5454,1532,8681,6364,5272,782
Debt  5,6702,1502,7472,5622,382
Other liabilities175341420529423497414
Other undisclosed current liabilities17,83614,34215,26415,65310,6267,7076,928
Total current liabilities:25,34030,54831,27427,28419,28522,75517,754
Noncurrent Liabilities
Long-term debt and lease obligation 58230,52634,81737,69738,40139,084
Long-term debt, excluding current maturities  24,08827,56929,68129,64229,603
Operating lease, liability 5826,4387,2488,0168,7599,481
Liabilities, other than long-term debt  879716553390227
Other liabilities  879716553390227
Other undisclosed noncurrent liabilities (582)     
Total noncurrent liabilities:  31,40535,53338,25038,79139,311
Total liabilities:25,34031,13062,67962,81757,53561,54657,065
Stockholders' equity
Stockholders' equity attributable to parent377,319410,724442,770471,981315,526337,58448,152
Common stock5555443
Additional paid in capital863,132856,460850,991846,305660,443656,973343,327
Accumulated other comprehensive income (loss)(2)3134255(90)(6)1
Accumulated deficit(485,816)(445,744)(408,360)(374,584)(344,831)(319,387)(295,179)
Total stockholders' equity:377,319410,724442,770471,981315,526337,58448,152
TOTAL LIABILITIES AND EQUITY:402,659441,854505,449534,798373,061399,130105,217

Income statement (P&L) ($ in thousands)

3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
Revenues 220   94 
Sublease income     94 
Gross profit:     94 
Operating expenses(40,226)(35,899)(33,378)(29,587)(25,983)(24,057)(21,051)
Other undisclosed operating loss     (94) 
Operating loss:(40,226)(35,899)(33,378)(29,587)(25,983)(24,057)(21,051)
Nonoperating income (expense)154(1,485)(398)(142)554(127)(98)
Investment income, nonoperating1543024596861,404730507
Interest and debt expense 1,063(857)(857)(850)(857)(605)
Loss from continuing operations before equity method investments, income taxes:(40,072)(36,321)(34,633)(30,586)(26,279)(25,041)(21,754)
Other undisclosed income (loss) from continuing operations before income taxes (1,063)8578578502,115 
Loss from continuing operations before income taxes:(40,072)(37,384)(33,776)(29,729)(25,429)(22,926)(21,754)
Income tax expense   (24)(15)  
Other undisclosed loss from continuing operations     (24) 
Loss before gain (loss) on sale of properties:(40,072)(37,384)(33,776)(29,753)(25,444)(22,950)(21,754)
Other undisclosed net loss     (1,258) 
Net loss:(40,072)(37,384)(33,776)(29,753)(25,444)(24,208)(21,754)
Other undisclosed net income attributable to parent      605
Net loss attributable to parent:(40,072)(37,384)(33,776)(29,753)(25,444)(24,208)(21,149)
Other undisclosed net loss available to common stockholders, basic     (6) 
Net loss available to common stockholders, diluted:(40,072)(37,384)(33,776)(29,753)(25,444)(24,214)(21,149)

Comprehensive Income ($ in thousands)

3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
Net loss:(40,072)(37,384)(33,776)(29,753)(25,444)(24,208)(21,754)
Comprehensive loss:(40,072)(37,384)(33,776)(29,753)(25,444)(24,208)(21,754)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(5)(131)(121)345(84)(1)595
Comprehensive loss, net of tax, attributable to parent:(40,077)(37,515)(33,897)(29,408)(25,528)(24,209)(21,159)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: